NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd.

纽约--（商业新闻短讯）--Nuvation Bio Inc.（纽约证券交易所：NUVB）是一家晚期全球生物制药公司，通过开发差异化和新型治疗候选药物来解决肿瘤学中一些最大的未满足需求，今天宣布完成对AnHeart Therapeutics Ltd.的收购。

(AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition’s completion, AnHeart is now a wholly-owned subsidiary of Nuvation Bio..

（AnHeart），一家为癌症患者开发新型精确疗法的晚期全球生物制药公司。收购完成后，AnHeart现在是Nuvation Bio的全资子公司。

“The closing of the acquisition transforms Nuvation Bio into a late-stage, global oncology company that is well-capitalized and positioned to develop our newly expanded pipeline as we move toward becoming a commercial organization,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Nuvation Bio的创始人、总裁兼首席执行官David Hung医学博士表示：“收购的完成将Nuvation Bio转变为一家资本充足的晚期全球肿瘤公司，在我们迈向商业组织的过程中，该公司将开发新扩建的管道。”

“We welcome the AnHeart team and look forward to leveraging our combined expertise to bring new cancer therapies to patients who need them most.”.

“我们欢迎AnHeart团队，并期待利用我们的综合专业知识为最需要的患者带来新的癌症治疗方法。”

Nuvation Bio will continue to be led by its current management team, including David Hung, M.D., its Founder, President, and Chief Executive Officer. In addition, Min Cui, Ph.D., Founder and Managing Director of Decheng Capital, an investor in AnHeart, and Junyuan Jerry Wang, Ph.D., Co-Founder and Chief Executive Officer of AnHeart, have joined the Nuvation Bio board of directors..

Nuvation Bio将继续由其现有的管理团队领导，包括其创始人、总裁兼首席执行官David Hung，医学博士。此外，AnHeart投资者德诚资本创始人兼董事总经理崔敏博士和AnHeart联合创始人兼首席执行官王俊元博士已加入Nuvation Bio董事会。

Following completion of the acquisition, Nuvation Bio issued to the AnHeart security holders, in exchange for all outstanding AnHeart shares, options, and other securities, approximately 43,590,188 shares of Nuvation Bio’s Class A common stock (inclusive of the shares of Class A common stock underlying the AnHeart equity awards assumed by Nuvation Bio), 851,202 shares of Nuvation Bio’s Series A Non-Voting Convertible Preferred Stock (automatically convertible into 85,120,200 shares of Nuvation Bio’s Class A common stock upon the approval of Nuvation Bio’s stockholders), and warrants collectively exercisable for approximately 2,893,731 shares of Nuvation Bio’s Class A common stock at an exercise price of $11.50 per share..

收购完成后，Nuvation Bio向AnHeart证券持有人发行了约43590188股Nuvation Bio A类普通股（包括Nuvation Bio承担的AnHeart股权奖励所依据的A类普通股），851202股Nuvation Bio A系列无投票权可转换优先股（经Nuvation Bio股东批准自动转换为85120200股Nuvation Bio A类普通股），以及可共同行使约2893731股Nuvation Bio A类普通股的认股权证，行权价格为11美元每股.50。

Advisors

顾问

Evercore acted as Nuvation Bio’s exclusive financial advisor and Cooley LLP acted as legal counsel, alongside Morrison & Foerster LLP as intellectual property counsel, Haiwen & Partners as Chinese legal counsel, and Conyers as Cayman Islands legal counsel. Davis Polk & Wardwell LLP acted as legal counsel for AnHeart, alongside Fangda Partners as Chinese legal counsel and Walkers (Cayman) LLP as Cayman Islands legal counsel..

Evercore担任Nuvation Bio的独家财务顾问，Cooley LLP担任法律顾问，Morrison＆Foerster LLP担任知识产权顾问，Haiwen＆Partners担任中国法律顾问，Conyers担任开曼群岛法律顾问。Davis Polk&Wardwell LLP担任AnHeart的法律顾问，Fangda Partners担任中国法律顾问，Walkers（Cayman）LLP担任开曼群岛法律顾问。

About Nuvation Bio

关于Nuvation Bio

Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC).

Nuvation Bio是一家晚期的全球生物制药公司，通过开发差异化和新颖的治疗候选药物来解决肿瘤学中一些最大的未满足需求。Nuvation Bio的开发候选者组合包括taletrectinib（ROS1），safusidenib（mIDH1），NUV-868（BET）和NUV-1511（DDC）。

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/..

Nuvation Bio于2018年由生物制药行业资深医生David Hung医学博士创立，他之前创立了Medivation，Inc.，该公司为患者带来了世界领先的前列腺癌药物之一。Nuvation Bio在纽约、旧金山和上海设有办事处。有关更多信息，请访问www.nuvationbio.com和https://www.linkedin.com/company/nuvationbio/.

Forward Looking Statements

前瞻性声明

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

根据1995年《美国私人证券诉讼改革法案》的安全港条款，本新闻稿中包含的某些非历史事实的声明是前瞻性声明。前瞻性陈述有时伴随着“相信”、“可能”、“会”、“估计”、“继续”、“预期”、“打算”、“期望”、“应该”、“会”、“计划”、“预测”、“潜在”、“看起来”、“寻求”、“未来”、“展望”等词语，以及预测或指示未来事件或趋势或不属于历史事项陈述的类似表达。

These forward-looking statements include, but are not limited to, the expected timing of establishing a commercial organization, potential therapeutic benefit of Nuvation Bio’s product candidates, development of our pipeline, and the sufficiency of Nuvation Bio’s current cash balance to fund ongoing activities.

这些前瞻性陈述包括但不限于建立商业组织的预期时间，Nuvation Bio候选产品的潜在治疗益处，我们管道的开发以及Nuvation Bio当前现金余额足以资助正在进行的活动。

These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the risk that the Acquisition may not close due to the failure of closing conditions to be satisfied or other reasons and the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associate.

这些声明基于各种假设，无论是否在本新闻稿中确定，以及Nuvation Bio管理团队目前的期望，而不是对实际表现的预测。这些前瞻性陈述受到许多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性陈述预期的结果不同，包括但不限于由于未能满足交割条件或其他原因导致收购可能无法完成的风险，以及由于监管过程中的困难或延迟，招募受试者或制造或获取必要产品而与进行药物发现和启动或进行临床试验相关的挑战；不良事件或其他不良副作用的出现或恶化；风险关联。